Wednesday, October 14, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 23, 2026

Once-in-a-Decade Opportunity: 1 AI Software Stock to Buy While It's Still Down

View original at nasdaq.com
Once-in-a-Decade Opportunity: 1 AI Software Stock to Buy While It's Still Down Key Points Salesforce's AI business is scaling rapidly, with Agentforce reaching annual recurring revenue of $800 million…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • All the top 10 deals secured by Salesforce in the fourth quarter included Agentforce

    60% confidence

  • Salesforce expects organic subscription and support revenue growth to reaccelerate in the second half of fiscal 2027

    60% confidence

  • More than 60% of Agentforce and Data 360 bookings were from existing customers

    60% confidence

  • The 10 best stocks for investors to buy now do not include Salesforce

    60% confidence

  • Salesforce stock seems like a smart buy now considering its relatively modest valuation alongside improving AI-powered growth indicators

    60% confidence

  • Stock Advisor's total average return is 898%, compared to 183% for the S&P 500

    60% confidence

Data points we hold from this source

Salesforce · remaining performance obligations72.4 USD
Salesforce · current rpo growth16 percent
Salesforce · current rpo35.1 USD
Salesforce · agentforce data360 arr growth200 percent
Salesforce · agentforce data360 combined arr2.9 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com